204 related articles for article (PubMed ID: 28849102)
1. Investigating the mechanisms of papillary thyroid carcinoma using transcriptome analysis.
Qiu J; Zhang W; Xia Q; Liu F; Zhao S; Zhang K; Chen M; Zang C; Ge R; Liang D; Sun Y
Mol Med Rep; 2017 Nov; 16(5):5954-5964. PubMed ID: 28849102
[TBL] [Abstract][Full Text] [Related]
2. The Landscape of Circular RNA Expression Profiles in Papillary Thyroid Carcinoma Based on RNA Sequencing.
Lan X; Xu J; Chen C; Zheng C; Wang J; Cao J; Zhu X; Ge M
Cell Physiol Biochem; 2018; 47(3):1122-1132. PubMed ID: 29847813
[TBL] [Abstract][Full Text] [Related]
3. Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-β type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis.
He J; Jin Y; Zhou M; Li X; Chen W; Wang Y; Gu S; Cao Y; Chu C; Liu X; Zou Q
Cancer Sci; 2018 Mar; 109(3):642-655. PubMed ID: 29274137
[TBL] [Abstract][Full Text] [Related]
4. Network-based meta-analysis in the identification of biomarkers for papillary thyroid cancer.
Zhao H; Li H
Gene; 2018 Jun; 661():160-168. PubMed ID: 29625265
[TBL] [Abstract][Full Text] [Related]
5. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
6. Competing endogenous RNA regulatory network in papillary thyroid carcinoma.
Chen S; Fan X; Gu H; Zhang L; Zhao W
Mol Med Rep; 2018 Jul; 18(1):695-704. PubMed ID: 29767230
[TBL] [Abstract][Full Text] [Related]
7. Identification of potential biomarkers and drugs for papillary thyroid cancer based on gene expression profile analysis.
Qu T; Li YP; Li XH; Chen Y
Mol Med Rep; 2016 Dec; 14(6):5041-5048. PubMed ID: 27779685
[TBL] [Abstract][Full Text] [Related]
8. Identification of Specific Long Non-Coding RNA Expression: Profile and Analysis of Association with Clinicopathologic Characteristics and BRAF Mutation in Papillary Thyroid Cancer.
Wang Q; Yang H; Wu L; Yao J; Meng X; Jiang H; Xiao C; Wu F
Thyroid; 2016 Dec; 26(12):1719-1732. PubMed ID: 27758138
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profile analyze the molecular mechanism of CXCR7 regulating papillary thyroid carcinoma growth and metastasis.
Zhang H; Teng X; Liu Z; Zhang L; Liu Z
J Exp Clin Cancer Res; 2015 Feb; 34(1):16. PubMed ID: 25887589
[TBL] [Abstract][Full Text] [Related]
10. RNA sequencing identifies crucial genes in papillary thyroid carcinoma (PTC) progression.
Qiu J; Zhang W; Xia Q; Liu F; Li L; Zhao S; Gao X; Zang C; Ge R; Sun Y
Exp Mol Pathol; 2016 Feb; 100(1):151-9. PubMed ID: 26708423
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory roles of miR‑9 on papillary thyroid cancer through targeting BRAF.
Gu Y; Yang N; Yin L; Feng C; Liu T
Mol Med Rep; 2018 Jul; 18(1):965-972. PubMed ID: 29767243
[TBL] [Abstract][Full Text] [Related]
12. Identification and analysis of genes associated with papillary thyroid carcinoma by bioinformatics methods.
Zhang S; Wang Q; Han Q; Han H; Lu P
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30872410
[TBL] [Abstract][Full Text] [Related]
13. Key genes and pathways predicted in papillary thyroid carcinoma based on bioinformatics analysis.
Yu J; Mai W; Cui Y; Kong L
J Endocrinol Invest; 2016 Nov; 39(11):1285-1293. PubMed ID: 27250077
[TBL] [Abstract][Full Text] [Related]
14. Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
Liyanarachchi S; Li W; Yan P; Bundschuh R; Brock P; Senter L; Ringel MD; de la Chapelle A; He H
J Clin Endocrinol Metab; 2016 Nov; 101(11):4005-4013. PubMed ID: 27459529
[TBL] [Abstract][Full Text] [Related]
15. Identification of Genes Associated with Papillary Thyroid Carcinoma (PTC) for Diagnosis by Integrated Analysis.
Li WB; Zhou J; Xu L; Su XL; Liu Q; Pang H
Horm Metab Res; 2016 Apr; 48(4):226-31. PubMed ID: 26756467
[TBL] [Abstract][Full Text] [Related]
16. Age at diagnosis and gender modify the risk of 9q22 and 14q13 polymorphisms for papillary thyroid carcinoma.
Kula D; Kalemba M; Puch Z; Polańska J; Świerniak M; Rusinek D; Żebracka-Gala J; Kowalska M; Handkiewicz-Junak D; Kowal M; Tyszkiewicz T; Piasna E; Czarniecka A; Pawlaczek A; Krajewska J; Szpak-Ulczok S; Jarząb B
Endokrynol Pol; 2017; 68(3):283-289. PubMed ID: 28660995
[TBL] [Abstract][Full Text] [Related]
17. Prediction Biomarkers Associated with Lymph Node Metastasis and Prognosis were Identified in Papillary Thyroid Carcinoma via Integrated Bioinformatics Analysis.
Gan S; Ye R; Ha Y; Xiong Y; Li R; Di X; Zou Z; Sun Y; Zhang Z
Comb Chem High Throughput Screen; 2021; 24(9):1395-1409. PubMed ID: 33155892
[TBL] [Abstract][Full Text] [Related]
18. Identification of key genes and miRNAs markers of papillary thyroid cancer.
Qiu J; Zhang W; Zang C; Liu X; Liu F; Ge R; Sun Y; Xia Q
Biol Res; 2018 Nov; 51(1):45. PubMed ID: 30414611
[TBL] [Abstract][Full Text] [Related]
19. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
[TBL] [Abstract][Full Text] [Related]
20. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
